Zobrazeno 51 - 60
of 56 281
pro vyhledávání: ''
Asparaginase activity monitoring and management of asparaginase hypersensitivity reactions in Canada
Publikováno v:
Journal of Oncology Pharmacy Practice. 29:105-111
Introduction Pegaspargase can cause anti-asparaginase antibody formation, which can decrease its effectiveness without causing any clinically apparent reaction (silent inactivation). When a patient has silent inactivation, a switch to Erwinia anti-as
Publikováno v:
Clinical and Translational Oncology. 24:854-863
BACKGROUND Resveratrol, a naturally occurring polyphenolic compound, has been shown to inhibit cancer growth by targeting several cancer-related signalling pathways. In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are the mos
Autor:
Yunfei Wang, Yin Wan, Nicholas J. Vogelzang, Yiqiong Xie, Nicholas J. Robert, Alisha M. Monnette, Nizar M. Tannir
Publikováno v:
Clinical Genitourinary Cancer. 19:531-539
Introduction Few studies have evaluated real-world effectiveness of lenvatinib (Len)/everolimus (Eve) for advanced/metastatic renal cell carcinoma (a/mRCC). This study evaluated patient profiles and clinical outcomes of second- and subsequent-line (
Autor:
Ronald Man Lung Yip, Cheuk Wan Yim
Publikováno v:
Journal of Clinical Rheumatology
Rheumatoid arthritis (RA) is a multisystem disease that affects the joints and various organs, resulting in compromised quality of life and increased mortality. A wide spectrum of treatment options is available for RA. Conventional synthetic disease-
Autor:
Clara Mayo de las Casas, Maria Gonzalez-Cao, Sebastian Ochenduszko, Juana Oramas, Miguel Angel Molina, Eva Muñoz-Couselo, Ana Arance, Roberto Diaz Beveridge, Miguel A Berciano-Guerrero, Enrique Espinosa, Luis de la Cruz, Delvys Rodriguez, Pablo Cerezuela, Ana Drozdowskyj, L. Bellido, Clara Montagut, Teresa Puertolas, Laura Basterretxea, Jose A. Lopez-Martin, Alfonso Berrocal, Maria-Jose Villanueva, Begoña Campos
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-6 (2021)
Nature Communications
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
NATURE COMMUNICATIONS
r-FISABIO. Repositorio Institucional de Producción Científica
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Nature Communications
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
NATURE COMMUNICATIONS
r-FISABIO. Repositorio Institucional de Producción Científica
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these d
Autor:
Neal D. Shore, Louise Yu, Dominique Lejeune, S. Ghate, François Laliberté, Jeri Kim, Lingfeng Yang, Mei Sheng Duh, Malena Mahendran, Raluca Ionescu-Ittu
Publikováno v:
Clinical Genitourinary Cancer. 19:480-490
Background Real-world evidence suggest that next generation hormonal agents (NHAs) abiraterone and enzalutamide were preferred as first-line (1L) therapies for metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) pre-2020
Autor:
Ainsley Barry, Tina Mills-Baldock, Sam Khan, Timothy Iveson, Athanasios Pouptsis, Chloe Holden, Anne Thomas, Bryony Eccles, Liyana Satterthwaite, Vasileios Angelis, Christina Karampera, Paul Ross, Sherif Abdel-Raouf, Alicja Synowiec, Kai-Keen Shiu, Maria Martinou, M Hill, Meera Chauhan, Mark Baxter, Chara Stavraka, Janet Graham, Sally Young
Publikováno v:
Clinical Colorectal Cancer. 20:342-349
BACKGROUND The orally administered combination trifluridine/tipiracil has been approved as third line treatment in mCRC, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study. PATIENT AND METHODS We performed
Autor:
Rodney P. Rocconi, Seema Singh, Kunwar Somesh Vikramdeo, Mohammad Aslam Khan, Santanu Dasgupta, Sarabjeet Kour Sudan, Annelise M. Wilhite, Ajay P. Singh
Publikováno v:
Semin Cancer Biol
Resistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer, contributing to the high mortality-to-incidence ratio. Management of the platinum-resistant disease has been difficult due to diverse underlying molecular mech
Autor:
E.J. Hovey, Mark Rosenthal, Elizabeth H Barnes, H.W. Sim, Helen Wheeler, Lawrence Cher, Anna K. Nowak, John Simes, Kathryn M. Field
Publikováno v:
Journal of Clinical Neuroscience. 94:321-327
Assessment of neurocognitive function (NCF) is important in brain tumor clinical trials, however there are varying methodologies available. We used the Cogstate computerized NCF testing battery and the mini-mental state examination (MMSE) to prospect
Publikováno v:
Clinical Genitourinary Cancer. 19:e395-e400
Background Renal medullary carcinoma (RMC) is a very rare, aggressive neoplasm occurring almost exclusively in adolescents and young adults with sickle cell trait. Given the rare nature of this tumor, accounting for less than 0.5% of all renal carcin